AbbVie, Inc. (ABBV)
261.67
+1.68
(+0.65%)
USD |
NYSE |
Sep 02, 16:00
261.80
+0.13
(+0.05%)
After-Hours: 19:41
AbbVie Research and Development Expense (TTM) : 9.714B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.714B |
| March 31, 2026 | 9.501B |
| December 31, 2025 | 9.096B |
| September 30, 2025 | 8.815B |
| June 30, 2025 | 8.626B |
| March 31, 2025 | 8.443B |
| December 31, 2024 | 8.315B |
| September 30, 2024 | 7.939B |
| June 30, 2024 | 7.531B |
| March 31, 2024 | 7.315B |
| December 31, 2023 | 7.668B |
| September 30, 2023 | 7.527B |
| June 30, 2023 | 7.415B |
| March 31, 2023 | 7.291B |
| December 31, 2022 | 6.487B |
| September 30, 2022 | 6.517B |
| June 30, 2022 | 6.562B |
| March 31, 2022 | 6.738B |
| December 31, 2021 | 6.981B |
| September 30, 2021 | 6.991B |
| June 30, 2021 | 6.911B |
| March 31, 2021 | 6.533B |
| December 31, 2020 | 6.181B |
| September 30, 2020 | 5.902B |
| June 30, 2020 | 5.582B |
| Date | Value |
|---|---|
| March 31, 2020 | 5.467B |
| December 31, 2019 | 5.377B |
| September 30, 2019 | 5.23B |
| June 30, 2019 | 5.243B |
| March 31, 2019 | 5.274B |
| December 31, 2018 | 5.229B |
| September 30, 2018 | 5.242B |
| June 30, 2018 | 5.202B |
| March 31, 2018 | 5.103B |
| December 31, 2017 | 4.994B |
| September 30, 2017 | 4.771B |
| June 30, 2017 | 4.595B |
| March 31, 2017 | 4.428B |
| December 31, 2016 | 4.239B |
| September 30, 2016 | 4.056B |
| June 30, 2016 | 4.404B |
| March 31, 2016 | 4.236B |
| December 31, 2015 | 4.101B |
| September 30, 2015 | 3.978B |
| June 30, 2015 | 3.39B |
| March 31, 2015 | 3.336B |
| December 31, 2014 | 3.297B |
| September 30, 2014 | 3.216B |
| June 30, 2014 | 3.118B |
| March 31, 2014 | 2.993B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biogen, Inc. | 1.736B |
| Gilead Sciences, Inc. | 5.943B |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Amgen, Inc. | 7.638B |
| REGENXBIO, Inc. | 213.77M |